Literature DB >> 6644568

Bayesian approach to bioequivalence assessment: an example.

H Fluehler, A P Grieve, D Mandallaz, J Mau, H A Moser.   

Abstract

The statistical methods required for a Bayesian analysis of bioequivalence are outlined and numerically illustrated. The analysis consists of the calculation of the posterior probability, given the experimental results, that the ratio of true means of a new and a standard formulation of a drug with respect to some biological response lies in a given interval. Nomograms helpful for the calculation of these probabilities are provided.

Mesh:

Year:  1983        PMID: 6644568     DOI: 10.1002/jps.2600721018

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

1.  Comparative bioavailability study of two brands of prazosin-containing tablets in healthy volunteers.

Authors:  P J Guelen; T J Janssen; M H Lam; T B Vree; P S Exler
Journal:  Pharm Weekbl Sci       Date:  1990-10-19

2.  Evaluation of bioequivalence studies.

Authors:  A P Grieve
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers.

Authors:  M T Maya; C R Domingos; M T Guerreiro; A P Filipe; J A Morais
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

4.  Average parameters as a trend to reduce the residual variability in bioequivalence trials.

Authors:  P Fagiolino; M Vazquez
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 5.  Review of methods and criteria for the evaluation of bioequivalence studies.

Authors:  G Pabst; H Jaeger
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

6.  A comparative bioavailability study to estimate the influence of an antacid on droxicam pharmacokinetics.

Authors:  M T Maya; J P Pais; J Ruas Da Silva; J A Morais
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Oct-Dec       Impact factor: 2.441

7.  The bioavailability of three altretamine formulations.

Authors:  E A Runhaar; J P Neijt; J J Holthuis; D de Vos
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

8.  Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions.

Authors:  V W Steinijans; H U Schulz; A Böhm; W Beier
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

9.  Generalization of distribution--free confidence intervals for bioavailability ratios.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  A non-parametric confidence interval method.

Authors:  A Racine-Poon; A P Grieve
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.